General Biosystems

Founded in 2014 and headquartered in San Diego, General Biosystems operates at the intersection of synthetic biology, AI/machine learning, and drug discovery. Its core innovation is a microchip-based gene synthesis technology, which it uses to offer a wide range of research services from oligo synthesis to custom protein production. The company appears to be a private, service-oriented platform, leveraging its scientific advisory board's expertise in genomics and antibody engineering to support its technology development and client projects.

Proprietary microchip-based gene synthesis platform enabling high-throughput, economical synthesis of oligonucleotide pools and gene libraries, integrated with software for genetic design and optimization, and empirical protein expression optimization systems.

General Biosystems competes in the gene synthesis and life science services market against large public players like Twist Bioscience and GenScript, as well as numerous other CROs. Its differentiation is claimed through its proprietary microchip synthesis technology and integrated biosystem optimization services, aiming to offer a unique combination of cost, speed, and design sophistication.